

INSTITUTIONAL REVIEW BOARD SUPPLEMENTAL FORM G GENETIC TESTING

PROTOCOL NUMBER

| 7 | 3 | 4 | 7 | 2 | Δ |
|---|---|---|----|---|---|
| • | 0 | - | .7 | ~ | ~ |

| 1. What type of samples will be used? |
|---|
| Blood samples for DNA testing. |
| |
| 2. From where and how will the samples be obtained? |
| Samples will be obtained via venipuncture using aseptic technique by the Clinical Research Center nursing staff during the course of the subject's admission for the study. |
| 3. Will the samples be identifiable or potentially identifiable through links or codes? Yes No If yes, please provide a justification why samples cannot be completely encrypted. |
| For purposes of the study, it is necessary to distinguish between samples from controls vs. patients and to distinguish between samples of patients with various diagnoses. |
| 4. What will be the purpose of taking the sample? |
| The purpose is to look for genetic markers for various endocrine disorders or puberty. |
| 5. Will the sample be destroyed after this purpose is served? If no, how will the sample be stored? |
| The sample will be stored frozen. |
| Where will the sample be stored? |
| In the Clinical Research Center. |
| How long will the sample be stored? |
| The sample will be kept indefinitely, since the possibility exists that new genetic markers could be found or new ways to find markers may be developed. |
| |

For Office Use Only: Q - 7 - 0 4
Supplemental Form G Page 1 of 2

4346132812

| 6. | Will additional purposes be devised for these samples? | Yes | Мо |
|----|--|---|-------|
| | If yes, please explain. | | |
| | | | |
| | | | |
| 7. | Will subjects receive any information back? If yes, please describe the information that subjects will receive. | Yes | X No |
| | II yes, prease describe the information that subjects will receive. | | |
| 8. | Who will "own" the sample? | | |
| Tl | he University of Chicago. | | |
| | | | |
| 9. | Will the University of Chicago investigator remain in control of the | sample? | |
| | If no, who will have control of the sample? | Yes | ☐ No |
| | | | |
| | | | |
| | | | j |
| | | | |
| | . Will the sample be shared with other University of Chicago investigations and the sample be shared? | ators? | No |
| | II yes, now will the sample be shared: | | |
| | | | |
| | | |] |
| | | | |
| | | | |
| | | | |
| 11 | . Will the sample be shared with investigators outside of the U of C? $$ | X Yes | No No |
| | If yes, how and with whom? | | |
| | Serum will be stored for assay of inhibin-B in subgroups via a collaborative arrangem Foster (University of Michigan). FAS will be assayed by RIA in collaboration with D Crowley, Jr., Massachusetts General Hospital. Blood (5-10 cc x 3) will be collected in DNA, prepare a lymphoblastoid cell line, and freeze in the CRC Core laboratory for s molicular genetic basis of idiopathic GnD in collaboration with Lawrence Layman, M | or. William F. n EDTA to ex tudies of the | . |